Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
SOUTH SAN FRANCISCO, Calif., March 28, 2016 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced its participation in two upcoming immuno-oncology conferences:
- The 6th Annual William Blair and Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality" Conference on Thursday, March 31, 2016 in New York, NY.
Dr. Chris Haqq, CMO of Atara Bio, will host a discussion entitled “The Power of Allogeneic T cell Banks Targeting Multiple Viral and Cancer Antigens” at 1:40 p.m. ET.
- Jefferies 2016 Immuno-Oncology Summit on Thursday, April 7, 2016 in Boston, MA.
Dr. Isaac Ciechanover, President and CEO of Atara Bio is scheduled to present at 7:30 a.m. ET, and will also host meetings with investors.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, with an initial focus on immunotherapy and oncology. Atara Bio's programs include T-cell product candidates and molecularly targeted product candidates. The T-cell product candidates include EBV-CTL, CMV-CTL and WT1-CTL and harness the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. The molecularly targeted product candidates include STM 434. These product candidates target activin and myostatin, members of the TGF-beta family of proteins, and have demonstrated the potential to have therapeutic benefit in a number of clinical indications.
INVESTOR & MEDIA CONTACT: Investors: Steve Klass 212-213-0006 x331 [email protected] Media: Justin Jackson 212-213-0006 x327 [email protected]
